Related Experiment Videos
Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity
A Hlobilkova1, P Guldberg, M Thullberg
1Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, Copenhagen O, DK-2100, Denmark.
Abstract:
PTEN, a tumor suppressor commonly targeted in human cancer, possesses phosphatase activities toward both protein and lipid substrates. While PTEN suppresses gliomas through cell cycle inhibition which requires its lipid phosphatase activity, PTEN's effects on other tumor types and the role of its protein phosphatase activity are controversial or unknown. Here we show that exogenous wild-type PTEN arrests some, but not all human breast cancer cell lines in G1, in a manner independent of endogenous PTEN. Unexpectedly, the G129E mutant of PTEN selectively deficient in the lipid phosphatase activity still blocked the cell cycle of MCF-7 cells, while the G129R and H123Y mutants lacking both phosphatase activities were ineffective. These results suggest that PTEN's protein phosphatase activity likely contributes to its tumor suppressor function in subsets of tumors and that elucidation of downstream targets which dictate cellular responses to PTEN may have important implications for future cancer treatment strategies.
Insights
The tumor suppressor PTEN
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- PTEN is a crucial tumor suppressor gene implicated in various cancers.
- Its known function involves lipid phosphatase activity, particularly in glioma suppression.
- The role of PTEN's protein phosphatase activity in other cancers remains unclear.
Purpose of the Study:
- To investigate the role of PTEN's protein phosphatase activity in human breast cancer.
- To determine if exogenous PTEN can inhibit breast cancer cell proliferation.
- To differentiate the effects of lipid versus protein phosphatase activity of PTEN.
Main Methods:
- Introduction of exogenous wild-type and mutant PTEN into human breast cancer cell lines.
- Cell cycle analysis (G1 arrest) was performed.
- Specific PTEN mutants with deficiencies in lipid or protein phosphatase activity were utilized.
Main Results:
- Wild-type PTEN induced G1 arrest in some breast cancer cell lines, independent of endogenous PTEN.
- A PTEN mutant (G129E) deficient in lipid phosphatase activity still inhibited cell cycle progression.
- PTEN mutants lacking both phosphatase activities (G129R, H123Y) failed to arrest cells.
Conclusions:
- PTEN's protein phosphatase activity contributes to tumor suppression in specific cancer types.
- Understanding PTEN's downstream targets is vital for developing novel cancer therapies.
- These findings highlight the complex roles of PTEN in cancer beyond its lipid phosphatase function.